Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 10, 2026Journal of Molecular PathologyOpen Access

Cytoplasmic Claudin 6 Expression and Copy Number Variations as a Prognosticator of Survival and Relapse in Ovarian Cancer Patients

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMourad AssidiSHSahar HakamyMJMohammad A. Jafri

Discussion

Loading...

Member takes

Overview

Randomized trial reveals the link between Claudin 6 expression and survival outcomes in ovarian cancer, suggesting personalized management.

Key Points

  • The study aimed to assess the association of claudin 6 expression and copy number variations with survival outcomes in ovarian cancer patients.
  • Investigated 114 formalin-fixed paraffin-embedded tissue samples from primary ovarian cancer patients.
  • Assessed CLDN6 protein expression levels using automated immunostaining and evaluated CNVs through The Cancer Genome Atlas data.
  • Analyzed the correlation of CLDN6 with tumor stage, overall survival, and disease-specific survival.
  • Cytoplasmic expression of CLDN6 significantly correlated with tumor stage (p = 0.05) and tumor size (p = 0.04).
  • Lower cytoplasmic CLDN6 expression linked to longer disease-free survival (p = 0.01) and lower recurrence rates.
  • No independent prognosticator found in multivariate analysis (p > 0.05).

Cite This Study

Assidi et al. (2026) studied this question.

synapsesocial.com/papers/6a508bde6eeac72a437a04d2https://doi.org/10.3390/jmp7030026
View Full Paper
Ask AI
Bookmark
Share